Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.56 |
| ▸ | HTR3B | O95264 | 4/20 | 0.56 |
| ▸ | HTR3A | P46098 | 4/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167113 | 0.85 | CXCR4 (0.49) | HRH4HRH3USP2KDM4ESORD | |
| SCHEMBL24799135 | 0.85 | SORD (0.48) | HRH4HRH3ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL31553317 | 0.83 | CXCR4 (0.51) | HRH4HRH3USP2KDM4ETDP1 | |
| SCHEMBL13750595 | 0.83 | CXCR4 (0.51) | HRH4HRH3USP2KDM4ETDP1 | |
| SCHEMBL206002 | 0.81 | SORD (0.46) | HRH4HRH3ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL5112284 | 0.81 | SORD (0.46) | HRH4HRH3ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL15698589 | 0.80 | SORD (0.52) | HRH4HRH3CYP3A4CYP2C19SORD | |
| SCHEMBL2166051 | 0.80 | HRH4 (1.00) | HRH4HRH3ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL6976678 | 0.80 | HRH3 (0.65) | HRH4HRH3HTR3EHTR3BHTR3A | |
| SCHEMBL29997962 | 0.80 | HRH4 (0.65) | HRH4HRH3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021018023-A1 | SMALL MOLECULE GLP-1 RECEPTOR MODULATOR | 济南泰达领创医药技术有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH4 2796/4885HRH3 2667/4885HTR3E 4562/4885 |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH4 2086/4885HRH3 2288/4885HTR3E 4411/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH4 2086/4885HRH3 2288/4885HTR3E 4411/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | HRH4 2403/4885HRH3 2143/4885HTR3E 3160/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | HRH4 2403/4885HRH3 2143/4885HTR3E 3160/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | HRH4 1565/4885HRH3 1439/4885HTR3E 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.